These findings underscore the important role of AKR1C1 in gefitinib resistance and present a new exciting strategy for targeting AKR1C1 to enhance the anti-tumor effects of gefitinib monotherapy, opening a new avenue for delaying gefitinib resistance in advanced NSCLC. This evidence concerns the gene AKR1C1 and neoplasm.